Trial Profile
A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Ampreloxetine (Primary)
- Indications Orthostatic hypotension
- Focus Registrational; Therapeutic Use
- Acronyms SEQUOIA
- Sponsors Theravance Biopharma
- 16 Nov 2023 Results published in the Theravance Biopharma Media Release.
- 16 Nov 2023 According to a Theravance Biopharma media release, anchor-based analysis of SEQUOIA and REDWOOD studies will be presented at the American Autonomic Society (AAS), taking place November 15-18, 2023.
- 28 Aug 2023 According to a Theravance Biopharma media release, results from this study were presented at the 2023 MDS Congress.